- Home
- RAPT vs CNTB Comparison
RAPT vs CNTB Comparison
Compare RAPT & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- CNTB
- Stock Information
- Founded
- RAPT 2015
- CNTB 2012
- Country
- RAPT United States
- CNTB United States
- Employees
- RAPT N/A
- CNTB N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- RAPT Health Care
- CNTB Health Care
- Exchange
- RAPT Nasdaq
- CNTB Nasdaq
- Market Cap
- RAPT 59.1M
- CNTB 53.9M
- IPO Year
- RAPT 2019
- CNTB 2021
- Fundamental
- Price
- RAPT $1.20
- CNTB $1.05
- Analyst Decision
- RAPT Hold
- CNTB Strong Buy
- Analyst Count
- RAPT 10
- CNTB 1
- Target Price
- RAPT $6.00
- CNTB $8.00
- AVG Volume (30 Days)
- RAPT 9.1M
- CNTB 28.0K
- Earning Date
- RAPT 03-06-2025
- CNTB 09-05-2024
- Dividend Yield
- RAPT N/A
- CNTB N/A
- EPS Growth
- RAPT N/A
- CNTB N/A
- EPS
- RAPT N/A
- CNTB N/A
- Revenue
- RAPT N/A
- CNTB $24,116,000.00
- Revenue This Year
- RAPT N/A
- CNTB N/A
- Revenue Next Year
- RAPT N/A
- CNTB $63.90
- P/E Ratio
- RAPT N/A
- CNTB N/A
- Revenue Growth
- RAPT N/A
- CNTB N/A
- 52 Week Low
- RAPT $0.79
- CNTB $0.90
- 52 Week High
- RAPT $27.35
- CNTB $2.66
- Technical
- Relative Strength Index (RSI)
- RAPT 43.92
- CNTB 45.74
- Support Level
- RAPT $1.07
- CNTB $1.01
- Resistance Level
- RAPT $1.29
- CNTB $1.40
- Average True Range (ATR)
- RAPT 0.17
- CNTB 0.13
- MACD
- RAPT -0.04
- CNTB -0.01
- Stochastic Oscillator
- RAPT 15.43
- CNTB 25.53
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.